JP2024508746A5 - - Google Patents
Info
- Publication number
- JP2024508746A5 JP2024508746A5 JP2023549549A JP2023549549A JP2024508746A5 JP 2024508746 A5 JP2024508746 A5 JP 2024508746A5 JP 2023549549 A JP2023549549 A JP 2023549549A JP 2023549549 A JP2023549549 A JP 2023549549A JP 2024508746 A5 JP2024508746 A5 JP 2024508746A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antigen
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150475P | 2021-02-17 | 2021-02-17 | |
| US63/150,475 | 2021-02-17 | ||
| PCT/US2022/016776 WO2022178114A1 (en) | 2021-02-17 | 2022-02-17 | Compositions comprising 4-1bb and ox40 binding proteins and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508746A JP2024508746A (ja) | 2024-02-28 |
| JP2024508746A5 true JP2024508746A5 (enExample) | 2025-02-21 |
Family
ID=80738990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549549A Pending JP2024508746A (ja) | 2021-02-17 | 2022-02-17 | ４－１ｂｂおよびｏｘ４０結合タンパク質を含む組成物および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240150483A1 (enExample) |
| EP (1) | EP4294843A1 (enExample) |
| JP (1) | JP2024508746A (enExample) |
| KR (1) | KR20230167025A (enExample) |
| CN (1) | CN117203236A (enExample) |
| AU (1) | AU2022223692A1 (enExample) |
| CA (1) | CA3208339A1 (enExample) |
| WO (1) | WO2022178114A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120584137A (zh) | 2023-01-06 | 2025-09-02 | 阿帕特夫研究和发展有限公司 | 双特异性pd-l1和cd40结合分子以及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP1712240B1 (en) * | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
| CA2785907A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| CN114181309B (zh) * | 2015-05-21 | 2024-07-30 | 鳄鱼生物科学公司 | 新型多肽 |
| MY197202A (en) * | 2017-03-16 | 2023-05-31 | Lg Chemical Ltd | A liquid formulation of anti-tnf alpha antibody |
| ES3044118T3 (en) * | 2018-07-12 | 2025-11-26 | Invox Pharma Ltd | Antibody molecules that bind cd137 and ox40 |
| BR112021013571A2 (pt) * | 2019-01-16 | 2021-09-21 | Compass Therapeutics Llc | Formulações de anticorpos que se ligam a cd137 humano e usos das mesmas |
| US20220242962A1 (en) * | 2019-08-12 | 2022-08-04 | Aptevo Research And Development Llc | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
-
2022
- 2022-02-17 WO PCT/US2022/016776 patent/WO2022178114A1/en not_active Ceased
- 2022-02-17 CN CN202280028792.6A patent/CN117203236A/zh active Pending
- 2022-02-17 KR KR1020237031740A patent/KR20230167025A/ko active Pending
- 2022-02-17 JP JP2023549549A patent/JP2024508746A/ja active Pending
- 2022-02-17 EP EP22710217.5A patent/EP4294843A1/en active Pending
- 2022-02-17 US US18/546,751 patent/US20240150483A1/en active Pending
- 2022-02-17 CA CA3208339A patent/CA3208339A1/en active Pending
- 2022-02-17 AU AU2022223692A patent/AU2022223692A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021245178B2 (en) | Stabilized antibody-containing liquid formulations | |
| JP2024016177A5 (enExample) | ||
| JP6469765B2 (ja) | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 | |
| CN106075434B (zh) | 含高浓度抗体的溶液制剂 | |
| EP3195880B1 (en) | High concentration anti-sclerostin antibody formulations | |
| JP2020518600A5 (enExample) | ||
| EP3681483B1 (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| RU2012131099A (ru) | Препарат антитела | |
| CN112741804A (zh) | 含有抗pd-l1抗体的稳定制剂 | |
| JP2020509031A5 (enExample) | ||
| JP2024508762A5 (enExample) | ||
| JP2024506940A5 (enExample) | ||
| JP2024540377A5 (enExample) | ||
| JP2024508746A5 (enExample) | ||
| JP7804590B2 (ja) | 抗ｉｌ－３３抗体の処方物 | |
| KR102725210B1 (ko) | 안정화된 Ace2 변이체, 이를 이용한 Ace2-Fc 융합단백질 및 COVID-19 예방 또는 치료용 약학 조성물 | |
| RU2025101286A (ru) | ФАРАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ РЕЦЕПТОРА ПРОГРАМИРУЕМОЙ СМЕРТИ 1 (PD-1) И rHuPH20 ИЛИ ИХ ВАРИАНТОВ ИЛИ ФРАГМЕНТОВ | |
| JP2024543931A5 (enExample) | ||
| RU2024127270A (ru) | Препараты, содержащие биспецифическое антитело против claudin18.2/cd3, способ их получения и применение | |
| EA043419B1 (ru) | Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка | |
| HK40033832B (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| HK40033832A (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein |